Julian Upton

Julian Upton is a contributing editor for Pharmaceutical Executive.

Articles by Julian Upton

After helping lead Novo Nordisk on a transformational journey from a troubled 2016 to double-digit growth in 2021, Doug Langa, Executive Vice President, Head of North America Operations and President of Novo Nordisk, Inc., is calling on his experience of taking the less conventional and sometimes unexpected routes to success to lead Novo Nordisk into new territory.

Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.

As the pressure on teams reviewing promotional content has increases, both in terms of volumes of content and complexity, Sameer Lal discusses the need for a near-term strategies using artificial intelligence (AI) and machine learning (ML) to decongest bottlenecks of the manual review process.

After two decades at the forefront of hematology and oncology drug development, AbbVie’s vice president and global head of oncology clinical development, Mohamed Zaki, MD, PhD, is more hopeful than ever about recent advances in the space.

Traditionally difficult in pharma, data science recruitment witnessed a sharp drop-off at the beginning of the pandemic, but interest has since bounced back to unexpected levels.

Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.

Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.

Amgen AstraZeneca Tezepelumab

AstraZeneca’s Mina Makar and Amgen’s Kave Niksefat talk about how the two companies worked together to develop the new asthma treatment, tezepelumab.

D&I at GSK

GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments.

Along with the industry’s massive effort to tackle the health and social problems exposed by COVID, pharma companies have spent the last year addressing the internal impact of racial inequalities following the murder of George Floyd.

Latest Updated Articles